On-Demand Symposium

Next Generation Sequencing in Lymphoid Research - Advances and Applications

Symposium from the 20th Meeting of the European Association for Haematopathology (EAHP)

Symposium Overview

As part of the 20th Meeting of the European Association for Haematopathology virtual event, Thermo Fisher Scientific hosted an educational industry symposium focused on the uses of next-generation sequencing (NGS) in lymphoid research.

Next-generation sequencing (NGS) is increasingly being adopted for BCR and TCR sequence analysis, as well as targeted gene panels in lymphoma research. NGS has advantages over other more traditional approaches as it provides low limits of detection (LOD), and a greater flexibility to multiplex.

Our customers shared their valuable experience on the value of NGS in this on-demand presentation.

Speakers & Topics

marainne-headshot

 

Lymphoma NGS Molecular Characterization - Assessing the Journey to Answers

Marianne Grantham
Head of Cytogenetics and Molecular Haematology | Barts Health NHS Trust 

Marianne Grantham presents an educational talk on current research on profiling lymphoma samples, the different requirements for different disease types and the benefits of using Next Generation Sequencing for this purpose.

hummel-headshot

 

The Time is NOW for NGS-Based Clonality Testing

Michael Hummel
Head of Molecular Pathology | Charité – Universitätsmedizin Berlin

Michael Hummel presents the background and history of clonality testing in Lymphomas and how NGS can improve on more traditional methods. With early access data from our yet to launch Ion Torrent ™ Oncomine ™ Pan-clonality BCR assay, he illustrates his points on the benefits and why laboratories should move the NGS based testing.

artur-headshot

 

Next Generation Sequencing for B Cell Receptor Sequencing in Multiple Myeloma: Uses and Impact

Artur Kowalik
Head Department Molecular Diagnostics | Holy Cross Cancer Center

Artur Kowalik presents his work on Multiple Myeloma and the value of NGS for detecting rare clones and the ability to track these clones at different stages of disease. He presents early access data from our yet to launch Ion Torrent ™ Oncomine ™ Pan-clonality BCR assay.

You May Also Like

Ready To Learn More?


Ask our NGS experts any questions or subscribe to get helpful updates from our team, including whitepapers, webinars, videos, case studies and more!

request-contact-cta

 

subscribe-now-cta